Skip to content
snus freak!
18+ only
Brands

Velo: the complete brand guide

VELO's ownership, range, strengths, formats and regulatory position, built from BAT filings, statutes and published studies. No scores: nothing has been tested.

by Jose Del Pozo 13 min read
Line illustration of a plain nicotine pouch can on a dark background, with the article title.

VELO is British American Tobacco’s nicotine pouch brand, launched in 2018, sold in 49 countries, and the second-largest pouch brand in the United States by volume and value share. The range runs from 3 mg to 17 mg per pouch depending on market, in Slim, Mini, Nano and Comfort formats. It is not on FDA’s authorised list, which matters in the US; it is prohibited outright in several European markets; and no authority has ever publicly named it as a counterfeited brand.

This is a brand profile built from company filings, statutes and published studies — not a review. No VELO product has been tested for this site, so there are no scores and no tasting notes. For the other half of the category see ZYN: the complete brand guide, and for the wider field, the brand directory.

The company

VELO is BAT’s own flagship in what the company calls Modern Oral. BAT’s 2025 annual report puts it plainly: “Launched in 2018, Velo is our flagship brand in the Modern Oral category, and it has grown to become a leading oral nicotine product.” The products themselves are described as “white in colour and contain high-purity nicotine, water and other high-quality food-grade ingredients, including plant-based fibres, flavouring and sweeteners.”

The scale is growing fast: “Volume was up 47.1% to 12.2 billion pouches. Revenue increased 47.4% to £1,165 million.” Products are available in 49 countries, and BAT names its top Modern Oral markets by industry revenue as “U.S., Sweden, Denmark, Norway, Switzerland, the UK and Poland,” together around 90% of the category’s industry revenue in 2024. One figure often attached to VELO is worth correcting: the 34.1 million consumers BAT reports is for Vuse, glo and VELO together. No VELO-only consumer number is published, so there is no honest way to quote one.

The US history is the part most often got wrong, and the record is clean. On 20 October 2020 BAT acquired “the formulations, brands, associated know-how and other relevant assets owned by Dryft Sciences, LLC (DSL) relating to its white nicotine pouch products” — an asset purchase, not a company purchase, made through Modoral Brands Inc., “an indirect, wholly owned subsidiary of BAT’s US subsidiary, Reynolds American Inc.” That portfolio was rebranded: the deal “enables a significant expansion of the Velo product range into the high-growth >6mg nicotine segment,” and “these products have been rebranded Velo and expands the US portfolio from 4 to 28 variants.” The commercial result is in the 2025 report: US revenue up 297% and “the number 2 position in both volume and value share.”

Where it is made is unsettled from public sources, and I am not going to pretend otherwise. BAT’s filings name only two Modern Oral sites — “our Modern Oral factory in Pécs, Hungary,” the first BAT site to obtain ISO 22000 food-safety certification, and “our facility in Trieste, Italy,” providing “additional capacity” — and have described Pécs that way since at least the FY2021 filing. VELO’s Swedish site, meanwhile, tells Swedish consumers “De flesta av VELOs produkter tillverkas i Sverige,” while the UK site declines to be specific: VELO “was born in Sweden and is produced in Europe. Please refer to the label on your VELO can for specific manufacturing details.” No BAT document I could find names a Swedish Modern Oral factory at all. Three sources, three answers, and I am reporting all three rather than picking one.

LYFT was BAT’s earlier European pouch brand, consolidated into VELO. BAT’s FY2020 filing records Board “oversight of progress across the Group to transition certain Modern Oral product brands to Velo,” which dates the consolidation to 2020 without naming LYFT; VELO’s Danish site gives the reason rather than the date — BAT “har ønsket at skabe ét brand med det samme navn i alle lande.” LYFT has not fully disappeared; the Danish site still sells it as a sub-brand. No BAT document states a rebrand year, so I am not giving one.

The range and the strengths

Strengths and even flavour names are market-specific, so a single global range table would be fiction. BAT’s own global statement is the safest summary: the range “spans across tobacco, mint and fruit flavours and is sold in various nicotine strengths, from 3mg to 17mg of nicotine per pouch.”

The UK range, read from VELO’s own product feed on 20 October 2026, offers 4, 6, 8, 10, 11, 14 and 17 mg across roughly two dozen flavours in Slim, Mini and Nano. Freezing Peppermint is listed at Slim 11, 14 and 17 mg, and VELO’s copy calls it “our strongest menthol experience of all our flavours.” VELO’s UK FAQ still lists “4mg, 6mg, 10mg and 11mg” as the current strengths, which the live store contradicts — cite the store, not the FAQ. Sweden runs 0, 4, 6, 8, 10, 10.9, 14 and 17 mg, including nicotine-free Zero variants the UK does not list, in Slim, Mini and Comfort. The 10.9 is the interesting figure: the product the UK sells as 11 mg, Sweden lists as 10.9 mg. If you print 11 mg, say UK.

Sweden is also where VELO publishes more data than any brand I have looked at: four fields per product page — nicotine per gram, nicotine per pouch, pouch count, can weight. Bright Spearmint 14 mg lists “Nikotin (mg/g): 20 mg”, “Nikotin (mg/prilla): 14 mg”, “Antal påsar: 20” and “Vikt (g/dosa): 14”. That is a disclosure choice rather than compliance: Swedish law requires nicotine content and its distribution per dose, not milligrams per gram.

Pouch counts differ by market and the usual shorthand is wrong. Denmark: “Alle VELO og LYFT dåser indeholder 20 nikotinposer.” Sweden: “Samtliga produkter från VELO innehåller 20 prillor per dosa.” But the UK: “There are 20 nicotine pouches in a slim can and 15 pouches in a mini can.” So “all VELO cans hold 20” is true in Scandinavia and false in Britain.

VELO does not publish a pouch weight on any market site I checked. The figure exists in the literature, from BAT’s and Reynolds’ own scientists, who describe their US test articles as “Velo ONPs with varying nicotine content (4-12 mg per pouch), pouch size (600 mg or 400 mg)” — so roughly 0.6 g for Slim and 0.4 g for Mini in the US range. That is an industry-authored number and should be attributed to the study, not to the brand.

VELO Shift is the 2025 addition: “a new innovative pouch shape and hexagonal can made of 90% bio-based plastic (based on a mass balance approach),” in the Comfort format. Eight flavours, all at 8 mg.

Where it is legal, and where it is not

United States: not authorised, and not rejected. FDA’s authorised-products page, content current as of 21 August 2026, states: “This list is up to date. There are 43 nicotine pouch products authorized by the FDA. These are the only nicotine pouch products that may be lawfully sold in the United States.” No VELO product appears on it — nor any other BAT, Reynolds or Modoral pouch. The two companies on the list are Swedish Match USA and Helix Innovations.

Absence from that list is not a denial, and BAT draws the distinction itself: “The Group’s Velo products remain on the market in the U.S., pending the FDA’s decisions on their premarket tobacco product applications and there can be no assurance these applications will be granted. If the FDA denies a marketing authorisation, then the relevant product(s) would need to be withdrawn from the market.” Reynolds filed PMTAs by the September 2020 deadline; FDA has not decided them, and FDA does not publish pending applications. The authorised list is the only public register, and silence on it establishes nothing either way.

I checked the enforcement side three ways and found nothing. FDA’s marketing-orders register carries no Marketing Denial Order for any nicotine pouch from any company — every R.J. Reynolds MDO on it is a Vuse vapour product. A full-text search of FDA’s warning-letter database returns zero results for “modoral” and zero for “lyft”, and the sixteen hits for “velo” are all unrelated drug and device companies. So: unauthorised, no denial order, no warning letter.

Prohibited markets. The Netherlands bans them by statute: “Het is verboden tabak voor oraal gebruik of nicotineproducten zonder tabak voor oraal gebruik in de handel te brengen,” with a definition that names pouches explicitly — products “in de vorm van poeder, fijne deeltjes… met name die welke in portiezakjes of poreuze builtjes worden aangeboden.” Belgium’s royal decree of 14 March 2023 is blunter still: “Il est interdit de mettre sur le marché des pochettes de nicotine et des pochettes de cannabinoïde,” in force 1 July 2023 generally and 1 October 2023 for retailers. Germany’s position is administrative rather than statutory: the federal risk assessment institute records that pouches are “von den Länderbehörden als neuartige Lebensmittel eingestuft und wegen der Überschreitung der akuten Referenzdosis für Nikotin vom Markt genommen.” Australia closed in July 2026: the Australian Border Force states that “From 24 July 2026, nicotine pouches cannot lawfully be imported into or supplied in Australia” unless registered or covered by a statutory exemption, and that “Travellers cannot bring nicotine pouches into Australia.”

One correction to a common claim, including one this site has carried: Norway is not a banned market for this category. BAT lists Norway among its seven top Modern Oral markets by industry revenue, which is not something a company reports about a jurisdiction where the category is prohibited. VELO has no Norwegian country site, which is consistent with Norway’s strict advertising and display rules rather than with a sales ban. I could not open Norwegian primary legislation to state the rule precisely, so I am stating only the negative: the “banned” characterisation is contradicted by BAT’s own revenue disclosure, and anyone wanting Norway’s actual position needs Norwegian sourcing.

Two US states reach it through flavour law. Massachusetts defines a tobacco product as “a product containing or made or derived from tobacco or nicotine that is intended for human consumption, whether smoked, chewed, absorbed, dissolved, inhaled, snorted, sniffed or ingested by any other means” — “or nicotine” and “absorbed” together put tobacco-free pouches squarely in scope — and then prohibits any person from selling “any flavored tobacco product… to any consumer in the commonwealth.” Because characterising flavour there is anything “other than the taste or aroma of tobacco,” expressly including menthol and mint, and because the UK and Nordic VELO ranges contain no tobacco-flavoured variant at all, the entire range would be a flavoured tobacco product in Massachusetts.

California works through a certification list instead: to be sold there a covered product must appear on the state’s Unflavored Tobacco List, “otherwise, it is classified as a prohibited flavored tobacco product.” The list does carry nicotine pouches — ZYN entries and others are on it. No VELO product is. Every VELO variant carries a flavour name and most are explicitly cooling, so that is the expected result, and on the rule as the state states it, no VELO pouch may lawfully be sold in California. The state’s Attorney General also reads cooling sensations as flavours, Assembly Bill 3218 having clarified that the ban reaches products providing “a ‘cooling sensation,’ even if the product otherwise includes no characterizing flavor.”

Counterfeits

I went looking for enforcement records naming VELO and found none. That is the finding, not a gap in the reporting.

Counterfeit nicotine pouches are real and industrially produced. In August 2026 OLAF reported that Lithuanian authorities had dismantled “a large illegal factory producing counterfeit nicotine pouches in Kaunas,” seizing “more than 330.000 boxes with trademarks of well-known manufacturers” plus “nicotine that is classified as an acutely toxic substance,” with around 30 different product types and a presumed supply chain into “the Scandinavian and Baltic countries, as well as the United Arab Emirates.” Neither OLAF’s release nor the Lithuanian Customs Criminal Service release that it links to names a single counterfeited brand.

UK enforcement draws a distinction worth borrowing. When Oxfordshire Trading Standards secured guilty pleas in October 2026 over an Oxford shop, its own account separates the two problems precisely: the cigarettes were “counterfeit” and named by brand, while the nicotine pouches were “non-compliant” and not named at all. Kent Trading Standards’ 2025 detention of 66,000 tubs turned on labelling and strength — “the information on the packets is in Spanish,” some “shown to contain 50mg of nicotine” — and named other brands. Neither action mentions VELO.

Two further points cut against the brand rather than for it. VELO’s market sites carry no anti-counterfeit guidance of any kind — I searched the UK, Swedish and Danish FAQs and homepages for authenticity features, fake-spotting advice or a “buy only from” warning and found none. And BAT’s corporate illicit-trade material, where it claims an “expert team is able to forensically analyse seized products, determining counterfeits” using “security systems that work by tracing and authenticating our products,” does not mention pouches at all; those are claims made about cigarettes. I could not query the EU Safety Gate database — its API refuses authorisation from our environment — so that avenue is unresolved rather than negative.

The evidence base

There is exactly one independent laboratory check of VELO’s labelled nicotine content that I could find, and its result is favourable. Cohen and colleagues at Johns Hopkins and Portland State bought ten VELO variants in Karachi in 2022 and reported that “All brand variants indicated the nicotine content on the container (6, 10 or 14 mg/pouch)… Measured nicotine levels were similar to the labelled values,” while flavour-chemical levels varied far more than nicotine did. Competing interests: “JEC has been a paid consultant in litigation against a tobacco company.” No funder is recorded in the indexed entry, so I cannot state one.

Most other VELO science is BAT’s or Reynolds’ own. BAT’s chemical characterisation paper — all three authors from BAT R&D — concluded that “use of NPs appears likely to expose users to lower levels of toxic compounds than Swedish snus,” and it is the footnote behind BAT’s reduced-risk claim in its own accounts, which is worth knowing when you read that claim. The clinical work is likewise in-house, and one of those papers discloses funder control unusually fully: “The funder had the following involvement in the study: study design, interpretation of data, the writing of this article, and the decision to submit for publication.” It found nicotine uptake slower and lower-peaking than cigarettes and “comparable or slightly lower than NRT gum.” Those are not independent results and should not be read as such.

For a market-wide, non-industry anchor, Germany’s BfR measured pouch weights of 0.38 to 1.1 g and nicotine of 3.04 to 17.90 mg per pouch across the products it bought — a range that brackets BAT’s stated 3–17 mg neatly, though it describes the category rather than this brand.

Verdict

On the record rather than the product: VELO is the most widely distributed pouch brand in the world, publishes the clearest specifications of any brand I have examined — on its Swedish site at least, where it volunteers four numbers per product that the law does not require — and the one independent check of its labelling found the labels accurate. Against that: its US regulatory position is unresolved rather than settled; it cannot lawfully be sold in California or Massachusetts on flavour grounds, or in the Netherlands, Belgium, Germany or Australia at all; most of the science supporting its risk profile is written by its own employees; and it publishes nothing to help a buyer tell a real tin from a fake one in a category where industrial counterfeiting is documented.

What I cannot tell you is whether it is good, because nothing has been tested. For strengths compared across brands on measured figures, see the strongest pouches by measured content and the master ranking. For what the numbers on a VELO tin mean, pouch weight versus nicotine content uses VELO’s Swedish figures as its worked example.

Sources

Last verified 20 October 2026. Three things I could not establish and have not asserted: a stated LYFT-to-VELO rebrand year in any BAT document; a single answer on where VELO is manufactured; and Norway’s current legal position from Norwegian primary sources. VELO’s US market site is unreachable from here, so the US range is sourced from BAT filings and published studies rather than from the brand.

Nicotine is addictive. No tobacco or nicotine product is safe, and completely stopping is the lowest-risk option. This site is for adults who already use nicotine — 21+ in the United States, 18+ or your local legal age elsewhere. Nothing here is medical advice.

Read this next